entity

Drug

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Drug: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

7Connections
19Hypotheses
0Analyses
7Outgoing
0Incoming
1Experiments
0Debates

No AI portrait yet

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Neurodegenerative Drug Development Pipeline

clinical · 1645 words

Alzheimer's Drug Discovery Foundation (ADDF)

institution · 3518 words

Exosome-Based Drug Delivery for CBS/PSP

therapeutic · 3343 words

NIH Drug Repurposing Program for Neurodegenerative Diseases

institution · 3160 words

Validated Hypothesis: STING Antagonists as ALS Therapeutics: Drug Repurposing

hypothesis · 2965 words

Nanoparticle Drug Delivery for Neurodegeneration

therapeutic · 2880 words

Outgoing (7)

TargetRelationTypeStr
Photoreceptorcausescell_type0.95
Ganglion Cellcausescell_type0.95
Retinal Pigment Epitheliumcausescell_type0.95
Photoreceptor Degenerationcausesphenotype0.95
Ganglion Cell Damagecausesphenotype0.90

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (19)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
STING Antagonists as ALS Therapeutics: Drug Repurposing 0.821 neuroinflammation How does chronic cGAS/STING activation d
early PD proteogenomic hubs that are both causal enough and 0.626 neurodegeneration Proteogenomic Network Hubs as Druggable
Cell-state stratification is required to resolve Proteogenom 0.612 neurodegeneration Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration Proteogenomic Network Hubs as Druggable
Tau-trafficking GWAS loci define a druggable PTK2B endocytos 0.592 alzheimers -
MALAT1 Three-Way Junction as a Druggable Target for Structur 0.591 molecular-biology What are the conserved secondary structu
Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibit 0.570 pharmacology How can CNS-selective HDAC/DNMT inhibito
MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CN 0.551 neuropharmacology What determines blood-brain barrier pene
Pharmacogenomic CNS Drug Optimization Platform 0.524 neurodegeneration How do neurodegeneration gene expression
Kinase Inhibitor-C1q Structural Convergence for Bifunctional 0.458 neuroinflammation How does Alectinib, a kinase inhibitor,
Glycan-Based Drug Delivery to Tau Vesicles 0.455 neurodegeneration Do tau-containing vesicles exhibit uniqu
Cathepsin-Dependent Processing of Pro-Drug Enzymes 0.400 neurodegeneration How does controlled lysosomal membrane p
IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability 0.397 drug-delivery Can IGFBPL1 therapeutics effectively cro
LDLR-Mediated Reverse Cholesterol Transport Modulation for C 0.380 neuropharmacology What is the actual quantitative contribu
Advancing Beyond Traditional Druggability Through RNA-Guided 0.000 - -
TREM2 Gradient-Based Drug Delivery 0.000 - TREM2 Therapeutic Strategy Post-INVOKE-2
Microglial NLRP3 Inflammasome as Circadian-Specific Drug Tar 0.000 - Can circadian interventions selectively
Condensate-Targeted Drug Delivery via Phase Partitioning 0.000 - What determines the specificity of DDR p
Advancing Beyond Traditional Druggability Through RNA-Guided 0.000 alzheimers -

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (1)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
12 newly identified AD-associated genes show prior evidence linking th computational Alzheimer's disease 0.500 0.00 in_vitro extracted N/A

Related Papers (7)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Activation of stimulator of interferon genes (STING) and inhibition of vascular [PMID:41380972] Wang Y, Hou Y, Han J, Zhang Z, Cheng Y e J Biol Chem 2026 0
cGAS-STING signaling in Alzheimer's disease: Microglial mechanisms and therapeut [PMID:41481960] Fazal F, Dar NJ, Ahamad S, Khan S, Bano Mol Aspects Med 2026 0
Opportunities and challenges of targeting cGAS-STING in cancer. [PMID:41486397] Lu C, Wang W, Fu YX Nat Rev Cancer 2026 0
cGAS-STING activation in Parkinson's Disease: From mechanisms to Disease-Modifyi [PMID:41500413] Solomon J, Mandal S, Aran KR Gene 2026 0
STING-NF-κB signaling builds an influenza spillover barrier. [PMID:41747053] Ye R, Wang S, Hu Y, Pan Y, Zheng W et al Science 2026 0
The cGAS-STING signaling pathway: A central regulator and novel therapeutic targ [PMID:41765111] Jiang H, Ji Y, Shang T, Qi L, Li Z et al Biochem Pharmacol 2026 0
cGAS-STING and PANoptosis: Interplay, Underlying Mechanisms, and Therapeutic Tar [PMID:42016387] Wang Y, Chen J, Feng W, Li N, Zhang X et Drug Des Devel Ther 2026 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning Drug in their description or question text

MALAT1 Three-Way Junction as a Druggable Target for Structure-Selective ASOs

Score: 0.591 · molecular-biology · 2026-04-21

## Mechanistic Overview MALAT1 Three-Way Junction as a Druggable Target for Structure-Selective ASOs starts from the cla

Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibition

Score: 0.570 · pharmacology · 2026-04-21

## Mechanistic Overview Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibition starts from the claim that modul

MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Reso

Score: 0.551 · neuropharmacology · 2026-04-13

## Mechanistic Overview MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Resolving Prodrugs s

Pharmacogenomic CNS Drug Optimization Platform

Score: 0.524 · neurodegeneration · 2026-04-12

## **Molecular Mechanism and Rationale** The pharmacogenomic CNS drug optimization platform leverages fundamental diffe

Kinase Inhibitor-C1q Structural Convergence for Bifunctional Drug Design

Score: 0.458 · neuroinflammation · 2026-04-16

## Mechanistic Overview Kinase Inhibitor-C1q Structural Convergence for Bifunctional Drug Design starts from the claim t

Glycan-Based Drug Delivery to Tau Vesicles

Score: 0.455 · neurodegeneration · 2026-04-27

Neuroprotective compounds conjugated to specific glycan structures would selectively accumulate in tau-containing vesicl

Cathepsin-Dependent Processing of Pro-Drug Enzymes

Score: 0.400 · neurodegeneration · 2026-04-21

## Mechanistic Overview Cathepsin-Dependent Processing of Pro-Drug Enzymes starts from the claim that modulating CTSD, U

IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability

Score: 0.397 · drug-delivery · 2026-04-22

## Mechanistic Overview IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability starts from the claim that modulating IG

LDLR-Mediated Reverse Cholesterol Transport Modulation for CNS Drug Delivery

Score: 0.380 · neuropharmacology · 2026-04-27

The LDLR-Mediated Reverse Cholesterol Transport Modulation strategy proposes that CNS drug delivery can be enhanced by h

TREM2 Gradient-Based Drug Delivery

Score: 0.000 · unknown disease · 2026-04-28

Nanomedicine approaches delivering TREM2 modulators to brain regions with optimal expression gradients for maximum thera

Microglial NLRP3 Inflammasome as Circadian-Specific Drug Target

Score: 0.000 · unknown disease · 2026-04-28

The NLRP3 inflammasome exhibits circadian oscillations regulated by BMAL1-dependent acetylation. Selective microglial ta

Condensate-Targeted Drug Delivery via Phase Partitioning

Score: 0.000 · unknown disease · 2026-04-28

Drugs designed with specific physicochemical properties could preferentially partition into pathological condensates, ac